Wegovy before and after results in men: what the trial data actually shows

What the trial data says about weight loss outcomes in men

The STEP 1 trial enrolled 1,961 adults with obesity or overweight plus at least one weight-related health condition. Across the full participant group, average body weight fell by around 15% on semaglutide 2.4mg over 68 weeks, against roughly 2.4% on placebo. Men were represented throughout, and sub-group analyses consistently show that biological sex affects the absolute kilograms lost more than the percentage: because men typically carry greater total body mass at baseline, a 15% reduction can translate to substantially more weight in real terms than the same percentage would for a lighter starting point.

It is worth being clear about what "average" means here. Some participants lost far more (trial data show that around a third of people on semaglutide lost 20% or more) while others lost considerably less. The NHS medicines information for semaglutide notes that stopping treatment typically leads to weight regain, which is why clinical oversight over the longer term matters. If you want to understand how long Wegovy takes to work at each stage of the titration, there is more detail on that separately.

One practical note many men find reassuring: the first pen (the 0.25mg dose) is a settling-in phase, not the therapeutic phase. The dose steps upward (typically every four weeks, as directed by your prescriber) before reaching the 2.4mg maintenance dose where trial weight-loss rates are recorded. If you want to see how the bigger shifts look in practice, the wegovy weight loss before and after pictures show how changes tend to build from month four onwards.

How men's results differ from aggregate figures, and why

Physiology shapes outcomes in a few consistent ways. Men generally have higher baseline muscle mass and metabolic rates, which can mean slightly faster early weight loss on a given calorie deficit. On the other hand, visceral fat, which is the kind concentrated around the abdomen and organs that tends to predominate in men with obesity, responds well to GLP-1 treatment: studies show semaglutide reduces visceral fat disproportionately relative to subcutaneous fat.

That abdominal shift is often what men notice first in terms of visible change, clothing fits differently around the waist before the scale moves dramatically. The broader results picture for Wegovy covers how those changes build across the treatment timeline. Men who add progressive resistance exercise during treatment consistently do better at preserving lean mass, which matters for long-term metabolic health long after any number on the scale.

One thing our prescribers hear regularly from men starting treatment: the first few weeks feel slow. That is normal. The titration schedule exists to reduce gastrointestinal side effects, not to delay results. Patience during the adjustment period tends to predict better adherence, and adherence is the single biggest driver of outcome in all of the trial sub-groups.

Side effects men report and how to manage them

The side-effect profile in men is broadly similar to the overall trial population. Nausea is the most commonly reported complaint, particularly in the first few weeks after each dose increase. Diarrhoea, constipation, indigestion, and fatigue appear regularly in the early stages and generally settle. In the STEP 1 trial, gastrointestinal events led around 4.5% of participants to discontinue treatment, a minority, but worth knowing.

Men who are physically active sometimes notice temporary drops in training performance during the titration phase, largely because appetite suppression can make it harder to eat enough to fuel exercise. Keeping protein intake high, staying well hydrated, and flagging performance concerns to your prescriber early helps. The MHRA monitors semaglutide closely, it carries a Black Triangle (▼) status, meaning any suspected side effects can be reported at the MHRA's Yellow Card scheme. Severe or persistent stomach pain that spreads to the back is a symptom that warrants urgent medical attention, not a wait-and-see approach.

For men considering costs alongside results, there is context on what Wegovy treatment involves (including what a legitimate private prescription includes) that is worth reading before making any decision.

What determines whether Wegovy is clinically suitable

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or a BMI of 27 or above where at least one weight-related health condition is present, conditions such as high blood pressure, raised cholesterol, obstructive sleep apnoea, or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. Meeting those parameters does not guarantee a prescription; the prescriber reviews the full clinical picture, including current medications, relevant history, and any contraindications.

Men who are considering treatment sometimes ask whether they need a referral or a waiting list. On the NHS, NICE recommends semaglutide within specialist weight management services and for a maximum of two years, meaning NHS access follows a specific pathway with its own criteria and waits. Private treatment through a GPhC-registered pharmacy is an alternative route that does not require a referral, the clinical assessment happens as part of the consultation itself.

If you have already looked at semaglutide results for men more broadly and want to see how individual journeys compare, the wegovy before and after examples give a useful sense of what realistic progress looks like before you check your eligibility with our prescribers. Consultations are free, reviewed the same day by a named GPhC-registered prescriber, and carry no obligation.